Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06005493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 11, 2023
Completion date
March 16, 2029
Enrollment
392 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric cancer, gastro-esophageal junction cancer, pancreatic ductal adenocarcinoma